Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in France / NCT05333367
Recruiting Not applicable

MORPHEE : Mechanisms of Cell Death Induced by Extracorporeal Photochemotherapy

NCT05333367 · tracked via the Priya Life Science France tracker
Sponsor
Centre Hospitalier Universitaire de Besancon
Phase
Not applicable
Started
2022-04-15
Last updated
2024-11-21

Condition(s) studied

Cutaneous T-Cell LymphomaGraft Vs Host DiseaseGraft Rejection

Investigational drug(s) / intervention(s)

Samples collection

Samples collection: Sampling of 2 samples on the extracorporeal photochemotherapy circuit, before and after sensitization with 8-MOP and UVA irradiation (without additional puncture)

Study summary

The objective of this study is to describe the type of cell death induced by extracorporeal photochemotherapy, depending on the cell type, using a panel of complementary analysis techniques.

Eligibility

Sex
ALL
Min age
18 Years
Max age
85 Years
Healthy volunteers
No
Inclusion Criteria: * Adult patients * Treated with ECP for at least 1 month, for control of GVHD in hematopoietic cell allograft (acute or chronic GVHD), treatment and control of cellular or humoral rejection in solid organ transplantation (heart, lung, kidney) or in the treatment of cutaneous T-cell lymphoma Exclusion Criteria: * Subjects with limited legal capacity. * Subjects judged by the investigator to be unlikely to comply with study procedures * Subjects with no social security coverage. * Pregnant women. * Subjects still in the exclusion period of another study, or according to the national registry of clinical trial participants.

Primary outcome measure(s)

  • Type of cell death induced by 8-MOP sensitization and UVA irradiation — 24 hours
    Caspase-3 activation in Western blot
  • Type of cell death induced by 8-MOP sensitization and UVA irradiation — 24 hours
    Gasdermin D cleavage in Western blot
  • Type of cell death induced by 8-MOP sensitization and UVA irradiation — 24 hours
    MLKL (mixed lineage kinase domain-like pseudokinase) phosphorylation in Western blot

Trial sites (1)

FacilityCityRegionStatus
Centre Hospitalier Universitaire de Besançon Besançon France Recruiting

More Centre Hospitalier Universitaire de Besancon trials in France

Study of Emotional Regulation and Underlying Prefrontal Activity in Binge Eating Disorder Recruiting
Combination of Spartalizumab, mDCF and Radiotherapy in Patients With Metastatic Squamous Cell Anal Carcinoma Recruiting
Identification of Innovative Biomarkers to Predict Outcomes in Hepatocellular Carcinoma Treated With Tremelimumab and Durvalumab Recruiting
Adverse Drug Events in Patients on Oral Anticoagulation in the Emergency Department Recruiting
Identification of Biomarkers Associated With the Presence of Malignant Pancreatic Lesions Compared to Benign Lesions. Recruiting

Other trials for the same condition

Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib. Active, not recruiting
Study of the Pathogenicity and Humoral Immune Response Induced by BK Virus in Lung Transplant Recipients Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05333367 on ClinicalTrials.gov ↗ ← All trials in France